QuidelOrtho Corporation (0A55.L)
| Previous close | 42.62 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 659 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 0.02 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
QuidelOrtho Opens New Distribution Center in Pedricktown, NJ
SAN DIEGO, May 15, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) has launched a second state-of-the-art United States distribution center in Pedricktown, New Jersey. This strategic endeavor epitomizes QuidelOrtho’s commitment to strengthening supply chain resilience and elevating the customer experience. In collaboration with a third-party logistics provider, this investment in redundancy and capacity is designed to enable QuidelOrtho to fulfill customer orders with agility.
- Business Wire
QuidelOrtho Reports First Quarter 2024 Financial Results
SAN DIEGO, May 08, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 31, 2024.
- Business Wire
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
SAN DIEGO, May 02, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company’s Board of Directors (the "Board") has appointed Brian J. Blaser as President and Chief Executive Officer ("CEO") effective May 6. In addition to his appointment as President and CEO, Mr. Blaser will join the Board, effective May 15, 2024
